Impact of Enzalutamide (ENZA) on Patient-Reported Outcomes (PROs) in metastatic Hormone-Sensitive Prostate Cancer (mHSPC) patients with no/low urinary symptoms at baseline: Results from the ARCHES study

• F. Saad,
• A.J. Armstrong,
• C. Ivanescu,
• H. Bhadauria,
• K. Ramaswamy,
• R. Morlock,
• B. Tombal

Affiliations

F. Saad

A.J. Armstrong

C. Ivanescu

H. Bhadauria

K. Ramaswamy

R. Morlock

B. Tombal